Biotechnology

Pharma giant AbbVie taps biotech innovator Alloy Therapeutics to build a novel antibody platform, aiming to unlock a new generation of medicines.

The biotech reports promising clinical data for its lead alpha-therapy program and secures funding into late 2027, navigating a high-cost, high-reward path.

In a new partnership, ALS Network and ALS United are seeking innovative ideas to accelerate breakthroughs, offering fresh hope to the ALS community.

A new one-time gene therapy shows it can clear toxic brain plaques in preclinical studies, offering a potential path to halt or even reverse Alzheimer's.

Following a key acquisition, biosolutions giant Novonesis leverages strong investor confidence to secure long-term financing for its strategic market expansion.

San Diego biotech elevates key execs as it advances its inflammation pipeline, backed by Sanofi and Lilly, into a competitive and high-stakes market.

A new compound could make CAR-T cell therapy more durable and less costly, showing promise against both cancer and HIV in groundbreaking new research.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

Nasus Pharma's NS002 nasal spray reached critical therapeutic levels in half the time of EpiPen, heralding a potential new era for anaphylaxis treatment.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

New data on an oral Parkinson's drug and major strides in rare disease research signal Lundbeck's deep commitment to tackling complex neurological disorders.

Swiss lab-tech firm Tecan posts a major loss after strategic write-downs but launches an ambitious 'Rewired' plan to chase a CHF 1B sales target.

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

OTC-listed ProText Mobility unveils an audacious plan to tokenize biotech assets, partner with major banks, and uplist to a major exchange. Can it deliver?

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

As it advances its brain cancer therapies, NeOnc Technologies hires a public company finance expert to steer its next growth phase and ensure fiscal rigor.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

A new iPSC-derived cell therapy from Unixell Biotech has gained FDA approval for clinical trials, offering a regenerative approach for millions with epilepsy.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

After a strategic pivot and R&D setbacks, Korro Bio secures an $85M lifeline to advance its novel RNA-editing drug for rare metabolic diseases.